Evogene Statistics
Total Valuation
Evogene has a market cap or net worth of ILS 30.71 million. The enterprise value is 43.39 million.
Market Cap | 30.71M |
Enterprise Value | 43.39M |
Important Dates
The last earnings date was Thursday, March 6, 2025.
Earnings Date | Mar 6, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Evogene has 6.51 million shares outstanding. The number of shares has increased by 24.14% in one year.
Current Share Class | n/a |
Shares Outstanding | 6.51M |
Shares Change (YoY) | +24.14% |
Shares Change (QoQ) | +17.02% |
Owned by Insiders (%) | 1.29% |
Owned by Institutions (%) | 6.67% |
Float | 6.43M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.87 |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -0.72 |
EV / Sales | 1.40 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -0.59 |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.17.
Current Ratio | 1.15 |
Quick Ratio | 0.90 |
Debt / Equity | 0.17 |
Debt / EBITDA | n/a |
Debt / FCF | -0.12 |
Interest Coverage | -352.54 |
Financial Efficiency
Return on equity (ROE) is -82.96% and return on invested capital (ROIC) is -58.86%.
Return on Equity (ROE) | -82.96% |
Return on Assets (ROA) | -30.52% |
Return on Invested Capital (ROIC) | -58.86% |
Return on Capital Employed (ROCE) | -104.92% |
Revenue Per Employee | 264,954 |
Profits Per Employee | -513,191 |
Employee Count | 117 |
Asset Turnover | 0.19 |
Inventory Turnover | 2.83 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.03% in the last 52 weeks. The beta is 1.18, so Evogene's price volatility has been higher than the market average.
Beta (5Y) | 1.18 |
52-Week Price Change | -83.03% |
50-Day Moving Average | 521.44 |
200-Day Moving Average | 829.84 |
Relative Strength Index (RSI) | 31.18 |
Average Volume (20 Days) | 10,564 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Evogene had revenue of ILS 31.00 million and -60.04 million in losses. Loss per share was -10.54.
Revenue | 31.00M |
Gross Profit | 21.23M |
Operating Income | -80.90M |
Pretax Income | -65.73M |
Net Income | -60.04M |
EBITDA | -74.68M |
EBIT | -80.90M |
Loss Per Share | -10.54 |
Balance Sheet
The company has 55.77 million in cash and 9.12 million in debt, giving a net cash position of 46.65 million or 7.16 per share.
Cash & Cash Equivalents | 55.77M |
Total Debt | 9.12M |
Net Cash | 46.65M |
Net Cash Per Share | 7.16 |
Equity (Book Value) | 54.04M |
Book Value Per Share | -0.81 |
Working Capital | 10.54M |
Cash Flow
In the last 12 months, operating cash flow was -71.75 million and capital expenditures -2.28 million, giving a free cash flow of -74.03 million.
Operating Cash Flow | -71.75M |
Capital Expenditures | -2.28M |
Free Cash Flow | -74.03M |
FCF Per Share | -11.36 |
Margins
Gross margin is 68.48%, with operating and profit margins of -260.96% and -193.69%.
Gross Margin | 68.48% |
Operating Margin | -260.96% |
Pretax Margin | -212.02% |
Profit Margin | -193.69% |
EBITDA Margin | -240.90% |
EBIT Margin | -260.96% |
FCF Margin | n/a |
Dividends & Yields
Evogene does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -24.14% |
Shareholder Yield | -24.14% |
Earnings Yield | -195.52% |
FCF Yield | -241.07% |
Stock Splits
The last stock split was on July 28, 2024. It was a reverse split with a ratio of 0.1.
Last Split Date | Jul 28, 2024 |
Split Type | Reverse |
Split Ratio | 0.1 |
Scores
Evogene has an Altman Z-Score of -10.5. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -10.5 |
Piotroski F-Score | n/a |